News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

Original Publication Date
Article Source
External Web Content
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative…

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia

Original Publication Date
Article Source
External Web Content
On September 1, 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG®, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery…

Understanding the Impact of Telomere Length and Mutations on Transplant Outcomes

Original Publication Date
Article Source
External Web Content
Advances in Hematologic Malignancies Issue 12, Summer 2020 — R. Coleman Lindsley, MD, PhD Identifying patients at high risk of fatal treatment toxicity is a central challenge in allogeneic hematopoietic stem cell transplantation (HSCT). More accurate prediction of non-relapse…

Guideline-based indicators for adult patients with myelodysplastic syndromes

Original Publication Date
Article Source
External Web Content
Key Points GBIs are measurable elements for quality of care and are currently lacking for adult MDS patients. We developed a GBI consensus for the domains of diagnosis (n = 14), therapy (n = 8), and provider/infrastructural characteristics (n = 7). Myelodysplastic syndromes (MDSs…

TP53 Mutation Status Possesses Prognostic Implications in MDS

Original Publication Date
Article Source
External Web Content
Patients with myelodysplastic syndromes (MDS) who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations, according to results from a study published in Nature…

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Original Publication Date
Article Source
External Web Content
Background Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult patients with haematological malignancies who…

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults

Original Publication Date
Article Source
External Web Content
In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia (AML) in older adults. Mikkael A. Sekeres, M.D., from the…

Oral Hypomethylating Agent Regimen Approved for MDS Improves Outpatient Treatment Options

Original Publication Date
Article Source
External Web Content
In an interview with Targeted Oncology, Guillermo Garcia-Manero, MD, discussed the FDA’s recent approval of oral decitabine and cedazuridine as treatment of patients with myelodysplastic syndromes and the data that supported this decision. In July 2020, the FDA granted approval…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families